$4.95
Today
as of Aug 5, 16:56 ET
Last 30 days
Recent Press Releases & News
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
Overview
52-week range
$1.13
$6.95
66% of range
Avg surprise (last 3)
+10.6%
Avg reaction (last 2)
+0.9%
50% positive
Latest IV / EM
94%
EM ±15.7% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.50 | $-0.49 | -2.0% | +25.4% | +3.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.37 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.37 | $-0.56 | +33.9% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.67 | $-0.67 | 0.0% | — | -1.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.56 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.24 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.14 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.79 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.85 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-38M | — | $-34M | $-36M | $-46M | — | $-51M | $-65M |
| Net income | $-35M | — | $-27M | $-27M | $-48M | — | $-40M | $-88M |
| EPS (diluted) | $-0.50 | — | $-0.37 | $-0.37 | $-0.67 | — | $-0.56 | $-1.24 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $32M | $36M | $39M | $38M | $42M | $34M | $41M | $37M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $218M | $253M | $288M | $312M | $343M | $386M | $400M | $440M |
| Total assets | $253M | $289M | $327M | $352M | $384M | $430M | $451M | $492M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $70M | $73M | $74M | $77M | $89M | $93M | $96M | $109M |
| Total equity | $183M | $216M | $253M | $274M | $295M | $337M | $354M | $383M |